Combination Nonviral Murine Interleukin 2 and Interleukin 12 Gene Therapy and Radiotherapy for Head and Neck Squamous Cell Carcinoma
Authors:
- Junming XianJXJunming Xian
- Huan YangHYHuan Yang
- Yinghe LinYLYinghe Lin
- Shixi LiuSLShixi Liu
Open Access
- 1 December 2005
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 131 (12) , 1079-1085
Abstract
More than 500 000 new patients each year worldwide contract head and neck cancers.1 During the past 30 years, the 3- to 5-year survival rate of patients with advanced T3 and T4 squamous cell carcinoma (SCC) of the head and neck (HNSCC) has remained poor (20%-30%) despite considerable advances in surgical techniques and irradiation delivery and improvement in chemotherapeutic strategies. Given these dismal figures, advances in gene therapy give new hope for primary or adjuvant treatment of HNSCC. Patients with HNSCC have been well documented to exhibit local immunosuppression with depressed T-cell–meditated responses as well as depressed natural killer (NK) cell and antibody-dependent cell cytotoxic effects.2Keywords
This publication has 10 references indexed in Scilit:
- Gene Therapy for Thyroid Cancer: Current Status and Future ProspectsThyroid®, 2004
- Effects of Combined Therapy With Interleukin 2 and Interleukin 12 Gene–Transfected Tumor Vaccine for Head and Neck CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2003
- Cure of an Established Nonimmunogenic Tumor, SCC VII, With a Novel Interleukin 12–Based Immunotherapy Regimen in C3H MiceJAMA Otolaryngology–Head & Neck Surgery, 2003
- Combination Nonviral Interleukin 2 Gene Therapy and External-Beam Radiation Therapy for Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2003
- Combination Nonviral Cytokine Gene Therapy for Head and Neck CancerThe Laryngoscope, 2001
- Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancerUrology, 1999
- A New Immunocompetent Murine Model for Oral CancerJAMA Otolaryngology–Head & Neck Surgery, 1997
- Interleukins 2 and 12 Activate Natural Killer Cytolytic Responses of Peripheral Blood Mononuclear Cells From Patients With Head and Neck Squamous Cell CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 1996
- Administration of Interleukin 12 With Pulse Interleukin 2 and the Rapid and Complete Eradication of Murine Renal CarcinomaJNCI: Journal of the National Cancer Institute, 1996
- Radiation-Induced Effects on Murine Kidney Tumor Cells: Role in the Interaction of Local Irradiation and ImmunotherapyJournal of Urology, 1995